Identifying radiographic specificity for phosphatase and tensin homolog and epidermal growth factor receptor changes: a quantitative analysis of glioblastomas

详细信息    查看全文

• 作者：Yinyan Wang (1) (2)
  Xing Fan (2)
  Chuanbao Zhang (2)
  Tan Zhang (1)
  Xiaoxia Peng (3)
  Tianyi Qian (4)
  Jun Ma (5) (8)
  Lei Wang (2) (6)
  Shaowu Li (5)
  Tao Jiang (1) (7)
  
• 关键词：Glioblastoma ; PTEN ; EGFR ; Voxel ; based mapping
• 刊名：Neuroradiology
• 出版年：2014
• 出版时间：December 2014
• 年：2014
• 卷：56
• 期：12
• 页码：1113-1120
• 全文大小：718 KB
• 参考文献：1. DeAngelis LM (2001) Brain tumors. N Engl J Med 344:114鈥?23 CrossRef
  2. Ohgaki H, Kleihues P (2005) Epidemiology and etiology of gliomas. Acta Neuropathol 109:93鈥?08 CrossRef
  3. Buckner JC (2003) Factors influencing survival in high-grade gliomas. Semin Oncol 30:10鈥?4 CrossRef
  4. Tanase CP, Enciu AM, Mihai S, Neagu AI, Calenic B, Cruceru ML (2013) Anti-cancer therapies in high grade gliomas. Curr Proteomics 10:246鈥?60 CrossRef
  5. Li J, Yen C, Liaw D, Podsypanina K, Bose S, Wang SI, Puc J, Miliaresis C, Rodgers L, McCombie R, Bigner SH, Giovanella BC, Ittmann M, Tycko B, Hibshoosh H, Wigler MH, Parsons R (1997) PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 275:1943鈥?947 CrossRef
  6. Ming M, He YY (2012) PTEN in DNA damage repair. Cancer Lett 319:125鈥?29 CrossRef
  7. Ortega-Molina A, Serrano M (2013) PTEN in cancer, metabolism, and aging. Trends Endocrinol Metab 24:184鈥?89 CrossRef
  8. Koul D (2008) PTEN signaling pathways in glioblastoma. Cancer Biol Ther 7:1321鈥?325 CrossRef
  9. Srividya MR, Thota B, Shailaja BC, Arivazhagan A, Thennarasu K, Chandramouli BA, Hegde AS, Santosh V (2011) Homozygous 10q23/PTEN deletion and its impact on outcome in glioblastoma: a prospective translational study on a uniformly treated cohort of adult patients. Neuropathology 31:376鈥?83 CrossRef
  10. Smith JS, Tachibana I, Passe SM, Huntley BK, Borell TJ, Iturria N, O鈥橣allon JR, Schaefer PL, Scheithauer BW, James CD, Buckner JC, Jenkins RB (2001) PTEN mutation, EGFR amplification, and outcome in patients with anaplastic astrocytoma and glioblastoma multiforme. J Natl Cancer Inst 93:1246鈥?256 CrossRef
  11. Carico C, Nuno M, Mukherjee D, Elramsisy A, Dantis J, Hu J, Rudnick J, Yu JS, Black KL, Bannykh SI, Patil CG (2012) Loss of PTEN is not associated with poor survival in newly diagnosed glioblastoma patients of the temozolomide era. PLoS One 7:e33684 CrossRef
  12. Ohgaki H, Kleihues P (2007) Genetic pathways to primary and secondary glioblastoma. Am J Pathol 170:1445鈥?453 CrossRef
  13. Pedersen MW, Poulsen HS (2006) Mutations in the epidermal growth factor receptor: structure and biological function in human tumors. Ugeskr Laeger 168:2354鈥?361
  14. Ellingson BM, Lai A, Harris RJ, Selfridge JM, Yong WH, Das K, Pope WB, Nghiemphu PL, Vinters HV, Liau LM, Mischel PS, Cloughesy TF (2013) Probabilistic radiographic atlas of glioblastoma phenotypes. AJNR Am J Neuroradiol 34:533鈥?40 CrossRef
  15. Kappadakunnel M, Eskin A, Dong J, Nelson SF, Mischel PS, Liau LM, Ngheimphu P, Lai A, Cloughesy TF, Goldin J, Pope WB (2010) Stem cell associated gene expression in glioblastoma multiforme: relationship to survival and the subventricular zone. J Neurooncol 96:359鈥?67 CrossRef
  16. Pore N, Liu S, Haas-Kogan DA, O鈥橰ourke DM, Maity A (2003) PTEN mutation and epidermal growth factor receptor activation regulate vascular endothelial growth factor (VEGF) mRNA expression in human glioblastoma cells by transactivating the proximal VEGF promoter. Cancer Res 63:236鈥?41
  17. Rong Y, Belozerov VE, Tucker-Burden C, Chen G, Durden DL, Olson JJ, Van Meir EG, Mackman N, Brat DJ (2009) Epidermal growth factor receptor and PTEN modulate tissue factor expression in glioblastoma through JunD/activator protein-1 transcriptional activity. Cancer Res 69:2540鈥?549 CrossRef
  18. Bates E, Wilson SM, Saygin AP, Dick F, Sereno MI, Knight RT, Dronkers NF (2003) Voxel-based lesion-symptom mapping. Nat Neurosci 6:448鈥?50
  19. Glascher J, Tranel D, Paul LK, Rudrauf D, Rorden C, Hornaday A, Grabowski T, Damasio H, Adolphs R (2009) Lesion mapping of cognitive abilities linked to intelligence. Neuron 61:681鈥?91 CrossRef
  20. Rousseaux M, Honore J, Vuilleumier P, Saj A (2013) Neuroanatomy of space, body, and posture perception in patients with right hemisphere stroke. Neurology 81:1291鈥?297 CrossRef
  21. Schwartz MF, Kimberg DY, Walker GM, Faseyitan O, Brecher A, Dell GS, Coslett HB (2009) Anterior temporal involvement in semantic word retrieval: voxel-based lesion-symptom mapping evidence from aphasia. Brain 132:3411鈥?427 CrossRef
  22. Kimberg DY, Coslett HB, Schwartz MF (2007) Power in voxel-based lesion-symptom mapping. J Cogn Neurosci 19:1067鈥?080 CrossRef
  23. Zhang W, Qiu XG, Chen BS, Li SW, Cui Y, Ren H, Jiang T (2009) Antiangiogenic therapy with bevacizumab in recurrent malignant gliomas: analysis of the response and core pathway aberrations. Chin Med J (Engl) 122:1250鈥?254
  24. Medina J, Kimberg DY, Chatterjee A, Coslett HB (2010) Inappropriate usage of the Brunner-Munzel test in recent voxel-based lesion-symptom mapping studies. Neuropsychologia 48:341鈥?43 CrossRef
  25. Zlatescu MC, TehraniYazdi A, Sasaki H, Megyesi JF, Betensky RA, Louis DN, Cairncross JG (2001) Tumor location and growth pattern correlate with genetic signature in oligodendroglial neoplasms. Cancer Res 61:6713鈥?715
  26. Lai A, Kharbanda S, Pope WB, Tran A, Solis OE, Peale F, Forrest WF, Pujara K, Carrillo JA, Pandita A, Ellingson BM, Bowers CW, Soriano RH, Schmidt NO, Mohan S, Yong WH, Seshagiri S, Modrusan Z, Jiang Z, Aldape KD, Mischel PS, Liau LM, Escovedo CJ, Chen W, Nghiemphu PL, James CD, Prados MD, Westphal M, Lamszus K, Cloughesy T, Phillips HS (2011) Evidence for sequenced molecular evolution of IDH1 mutant glioblastoma from a distinct cell of origin. J Clin Oncol 29:4482鈥?490 CrossRef
  27. Ellingson BM, Cloughesy TF, Pope WB, Zaw TM, Phillips H, Lalezari S, Nghiemphu PL, Ibrahim H, Naeini KM, Harris RJ, Lai A (2012) Anatomic localization of O6-methylguanine DNA methyltransferase (MGMT) promoter methylated and unmethylated tumors: a radiographic study in 358 de novo human glioblastomas. Neuroimage 59:908鈥?16 CrossRef
  28. Lim DA, Cha S, Mayo MC, Chen MH, Keles E, VandenBerg S, Berger MS (2007) Relationship of glioblastoma multiforme to neural stem cell regions predicts invasive and multifocal tumor phenotype. Neuro Oncol 9:424鈥?29 CrossRef
  29. Jafri NF, Clarke JL, Weinberg V, Barani IJ, Cha S (2013) Relationship of glioblastoma multiforme to the subventricular zone is associated with survival. Neuro Oncol 15:91鈥?6 CrossRef
  30. Verhaak RG, Hoadley KA, Purdom E, Wang V, Qi Y, Wilkerson MD, Miller CR, Ding L, Golub T, Mesirov JP, Alexe G, Lawrence M, O'Kelly M, Tamayo P, Weir BA, Gabriel S, Winckler W, Gupta S, Jakkula L, Feiler HS, Hodgson JG, James CD, Sarkaria JN, Brennan C, Kahn A, Spellman PT, Wilson RK, Speed TP, Gray JW, Meyerson M, Getz G, Perou CM, Hayes DN, Cancer Genome Atlas Research N (2010) Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 17:98 CrossRef
  31. Davis NM, Sokolosky M, Stadelman K, Abrams SL, Libra M, Candido S, Nicoletti F, Polesel J, Maestro R, D鈥橝ssoro A, Drobot L, Rakus D, Gizak A, Laidler P, Dulinska-Litewka J, Basecke J, Mijatovic S, Maksimovic-Ivanic D, Montalto G, Cervello M, Fitzgerald TL, Demidenko Z, Martelli AM, Cocco L, Steelman LS, McCubrey JA (2014) Deregulation of the EGFR/PI3K/PTEN/Akt/mTORC1 pathway in breast cancer: possibilities for therapeutic intervention. Oncotarget 5:4603鈥?650
  32. Matsuda S, Nakanishi A, Wada Y, Kitagishi Y (2013) Roles of PI3K/AKT/PTEN pathway as a target for pharmaceutical therapy. Open Med Chem J 7:23鈥?9 CrossRef
  33. Hegi ME, Rajakannu P, Weller M (2012) Epidermal growth factor receptor: a re-emerging target in glioblastoma. Curr Opin Neurol 25:774鈥?79 CrossRef
  34. Lv S, Teugels E, Sadones J, De Brakeleer S, Duerinck J, Du Four S, Michotte A, De Greve J, Neyns B (2012) Correlation of EGFR, IDH1 and PTEN status with the outcome of patients with recurrent glioblastoma treated in a phase II clinical trial with the EGFR-blocking monoclonal antibody cetuximab. Int J Oncol 41:1029鈥?035
  35. Liu W, James CD, Frederick L, Alderete BE, Jenkins RB (1997) PTEN/MMAC1 mutations and EGFR amplification in glioblastomas. Cancer Res 57:5254鈥?257
  
• 作者单位：Yinyan Wang (1) (2)
  Xing Fan (2)
  Chuanbao Zhang (2)
  Tan Zhang (1)
  Xiaoxia Peng (3)
  Tianyi Qian (4)
  Jun Ma (5) (8)
  Lei Wang (2) (6)
  Shaowu Li (5)
  Tao Jiang (1) (7)
  
  1. Beijing Neurosurgical Institute, Capital Medical University, No. 6 Tiantan Xili, Dongcheng District, Beijing, 100050, China
  2. Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China
  3. Department of Epidemiology and Biostatistics, School of Public Health and Family Medicine, Capital Medical University, Beijing, China
  4. Siemens Healthcare, MR Collaboration NE Asia, Beijing, China
  5. Department of Neuroradiology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China
  8. Department of Neuroradiology, Beijing Tiantan Hospital, Capital Medical University, No. 6 Tiantan Xili, Dongcheng District, Beijing, 100050, China
  6. China National Clinical Research Center for Neurological Diseases, Beijing, China
  7. Beijing Institute for Brain Disorders Brain Tumor Center, Beijing, China
  
• ISSN：1432-1920

文摘

Introduction Phosphatase and tensin homolog (PTEN) loss and epidermal growth factor receptor (EGFR) amplification are common genetic alterations in malignant gliomas. This study aimed to investigate the anatomical relationship of tumor-related PTEN and EGFR expression in 140 patients with histologically confirmed de novo glioblastoma. Methods Preoperative magnetic resonance images were retrospectively analyzed. The lesions of each patient were segmented manually and registered to a standard brain space. Overlaying of the lesions was performed, and specific brain regions associated with PTEN loss and EGFR amplification were identified by voxel-based lesion-symptom mapping analyses. Results A cluster located in the right frontal lobe was found to be associated with high occurrence of PTEN loss, whereas a cluster in the right parietal lobe was demonstrated to be specifically associated with high occurrence of EGFR amplification. An overlap of the two clusters was observed at the posterior portion of the right parietal lobe. Conclusions Based on voxel-based imaging analyses, our results suggest that genetic changes during the tumorigenic process may have anatomical specificity. We hope that this identified correlation between these biomarkers and the anatomical distribution of glioblastomas will help enhance our understanding of the molecular mechanisms underlying glioblastoma development and progression.